Artificial CAR T Cell Targets for Reproducible Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the functional capacity of CAR T cells are hindered by variability in live target cells, genetic drift, and handling issues, making standardization and consistency in bioassays challenging.
Innovation Solution
The use of artificial substrates with high-density, covalently bound anti-CAR idiotype antibodies and costimulatory molecules like CD28, either on particles or surfaces, to activate CAR T cells in an antigen-dependent manner, allowing for reproducible and biologically relevant activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live target cells are used for functional assays, then CAR T cell activation can be achieved, but high variability and batch-to-batch genetic drift occur
Solution Approach 1:
The patent replaces live target cells with artificial target particles that copy only the essential functional features (antigen expression, costimulatory molecules) while eliminating biological variability. These synthetic targets are produced through controlled chemical conjugation rather than biological culture, ensuring batch-to-batch consistency.
Solution Approach 2:
The invention transitions from biological parameters (live cell properties, genetic composition) to controlled chemical parameters (antibody conjugation density, particle size, surface chemistry). This parameter transformation enables precise control over target characteristics and eliminates genetic drift inherent in cellular systems.
2Measurement precision
If live target cells are used for functional assays, then CAR T cell activation can be measured, but handling variations during storage and cell culture occur
Solution Approach 1:
The patent employs disposable artificial target particles that can be prepared in bulk, stored under stable conditions, and used repeatedly without the handling complexities of live cells. These non-biological targets eliminate the need for cell culture maintenance, storage at specific temperatures, and contamination prevention protocols.
Solution Approach 2:
The invention extracts only the necessary functional components (antigen-binding capability, costimulatory signaling) from live target cells and transfers them to synthetic particles. This extraction eliminates the cumbersome biological infrastructure required for live cell handling while preserving the essential activation function.
3Reliability
If anti-idiotype antibody is used to activate CAR T cells, then antigen-specific activation is achieved, but biologically-relevant activation levels are not reached
Solution Approach 1:
The patent combines multiple activation signals on a single artificial target particle: anti-idiotype antibody for antigen recognition, CD28 costimulatory molecules for enhanced signaling, and optimized surface density for sufficient receptor clustering. This merging of signals achieves biologically relevant activation levels while maintaining specificity.
Solution Approach 2:
The artificial target is constructed as a composite structure combining synthetic particles, immunoglobulin molecules, costimulatory ligands, and crosslinking agents. This composite approach integrates multiple functional elements that work synergistically to achieve robust and specific CAR T cell activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables reliable and biologically relevant activation of CAR T cells, achieving activation levels comparable to live target cells, with improved reproducibility and scalability, suitable for quality control, potency assays, and CAR T cell expansion.
Implementation Method 1
incubating the sample with at least one substrate provided on its surface with at least one anti-CAR idiotype antibody
Implementation Method 2
with at least one costimulatory molecule selected from the group consisting of CD28, CD2, CD6, CD26, CD53 and LFA-1
Data Source
AI summary
The invention is directed to a method for activating CAR cells having at least one chimeric antigen binding receptor in a sample by incubating the sample with at least one substrate provided on its surface with at least one anti-CAR idiotype antibody and/or at least one antigen selected from the group consisting of CD19, CD20, CD22, BCMA, CD33, MSLN, CD123, HER2, GD2, EGFR, PSMA, MUC1, CD318, TSPAN8, CD66c, CEA, CLA, CD276, FolR1, CLEC12A, CLL-1 and CD371, and with at least one costimulatory molecule selected from the group consisting of CD28, CD2, CD6, CD26, CD53 and LFA-1 characterized in that the sample is incubated with the at least substrate in suspension thereby activating the CAR T cells to express markers selected from the group consisting of mRNA, effector molecules or cell surface activation markers.